Melatonin
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
Melatonin: Drug Repurposing Evaluation — No TxGNN Prediction Data Available
One-Sentence Summary
Melatonin (DB01065) is an endogenous neurohormone primarily associated with circadian rhythm regulation and sleep-wake cycle management. The current Evidence Pack contains no TxGNN predicted indications and carries two unresolved data gaps — one of which is classified as Blocking — meaning a formal repurposing evaluation cannot be completed at this stage. This report documents the current state of the evidence and outlines the steps needed before any repurposing decision can be made.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in Evidence Pack |
| Predicted New Indication | No predictions available |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A — pipeline has not produced output |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why Is This Prediction Reasonable?
No TxGNN prediction has been generated for this drug in the current Evidence Pack, so no mechanistic rationale for a new indication can be formally presented.
For general context: Melatonin (N-acetyl-5-methoxytryptamine) is an endogenous hormone synthesised primarily by the pineal gland. Based on publicly available pharmacological knowledge, it acts on G protein-coupled melatonin receptors MT1 and MT2, mediating entrainment of the circadian rhythm and sleep-wake transitions. It is also recognised as having antioxidant properties. The Evidence Pack, however, flags the mechanism of action as a High-severity data gap (DG002), meaning formal MOA documentation has not yet been retrieved from DrugBank.
Until the TxGNN prediction pipeline is re-run and produces candidate indications, this section will remain incomplete.
Clinical Trial Evidence
No TxGNN prediction has been generated for this drug. No disease-specific clinical trial evidence is presented in this Evidence Pack.
Currently no related clinical trials registered in the Evidence Pack.
Literature Evidence
No TxGNN prediction has been generated for this drug. No disease-specific literature evidence is presented in this Evidence Pack.
Currently no related literature available in the Evidence Pack.
Denmark Market Information
Melatonin is not currently recorded as marketed in Denmark within this Evidence Pack. No marketing authorisations from the Danish Medicines Agency (Laegemiddelstyrelsen) are on file.
| Item | Detail |
|---|---|
| Market Status | Not marketed in Denmark (per Evidence Pack) |
| Total Authorisations | 0 |
Note for reviewers: Melatonin is authorised in the European Union under the brand name Circadin® 2 mg prolonged-release tablet (EMA centralised procedure) for the short-term treatment of primary insomnia in patients aged 55 years and over. This authorisation does not appear in the current Evidence Pack, which may indicate a data collection gap rather than a true absence of authorisation. Verification against the Laegemiddelstyrelsen product database is recommended before concluding that melatonin is entirely unregistered in Denmark.
Safety Considerations
All safety fields in this Evidence Pack are flagged as data gaps and cannot be reported.
Please refer to the approved Summary of Product Characteristics (SmPC) — for example, the EMA-authorised Circadin SmPC — for current safety information, including warnings, contraindications, and drug interactions.
Outstanding data gaps preventing safety assessment:
| Gap ID | Missing Item | Severity | Impact | Suggested Remediation |
|---|---|---|---|---|
| DG001 | Regulatory warnings and contraindications | Blocking | Cannot complete safety pre-screening (S1 gate) | Download and parse SmPC PDF from Laegemiddelstyrelsen or EMA website |
| DG002 | Mechanism of action (MOA) | High | Mechanistic link analysis cannot be performed | Query DrugBank API for DB01065 |
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN pipeline has not produced any predicted indications for melatonin in this Evidence Pack version (v4, data cut-off 2026-04-04), and a Blocking data gap (DG001 — missing regulatory warnings and contraindications) prevents even preliminary safety screening. No repurposing evaluation can proceed until these issues are resolved.
To proceed, the following is needed:
- [Blocking] Resolve DG001: Retrieve current SmPC warnings and contraindications from Laegemiddelstyrelsen or the EMA product database
- [High] Resolve DG002: Query DrugBank API for DB01065 to obtain formal MOA documentation
- Re-run the TxGNN prediction pipeline after data gaps are resolved to generate candidate indications
- Verify Denmark registration status: Cross-check whether Circadin® or any melatonin product currently holds a national or centralised authorisation valid in Denmark, as the 0-licence count in this Evidence Pack may reflect a data collection issue
- Update the Evidence Pack to version v5 once the above steps are completed, and re-submit for formal evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.